Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

A. Prat1* M. Parera1 B. Adamo1 S. Peralta1 M. A. Perez-Benavente2 A. Garcia3 A. Gil-Moreno2 J. M. Martinez-Palones2 J. Baselga1 and J. M. del Campo1

首页> 外文期刊>Annals of Oncology >Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

【24h】

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

机译：最佳治疗的晚期上皮性卵巢癌（EOC）在随访期间复发的风险，血清CA-125水平低水平升高

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Our group evaluated the risk of recurrence for optimally treated advanced epithelial ovarian cancer (adEOC) in patients with a low-level rising serum CA-125 concentration within the normal range (0–35 kU/l). In addition, we tested the new proposed early CA-125 signal of progressive disease (EPD) criterion in the same study population.

机译：背景：我们的小组评估了血清CA-125浓度在正常范围（0–35 kU / l）中低水平升高的患者中最佳治疗的晚期上皮性卵巢癌（adEOC）复发的风险。此外，我们在同一研究人群中测试了新提出的进行性疾病早期CA-125信号（EPD）标准。

著录项

来源
《Annals of Oncology》 |2009年第2期|p.294-297|共4页
作者
A. Prat1* M. Parera1 B. Adamo1 S. Peralta1 M. A. Perez-Benavente2 A. Garcia3 A. Gil-Moreno2 J. M. Martinez-Palones2 J. Baselga1 and J. M. del Campo1;
展开▼
作者单位

1Department of Medical Oncology 2Department of Gynecologic Oncology 3Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. [J] . Santillan A, Garg R, Zahurak ML, Journal of Clinical Oncology . 2005,第36期

机译：血清CA-125水平升高至正常范围内的患者出现上皮性卵巢癌复发的风险。
2. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-(F-18)fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. [J] . Peng NJ, Liou WS, Liu RS, Cancer biotherapy and radiopharmaceuticals . 2011,第2期

机译：通过2-（F-18）氟-2-脱氧-D-葡萄糖-正电子发射断层显像/计算机断层摄影术，早期发现血清CA-125水平低水平升高的复发性卵巢癌患者。
3. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial [J] . RandallL.M., SillM.W., BurgerR.A., Gynecologic Oncology: An International Journal . 2012,第3期

机译：妇科肿瘤组II期临床试验对接受贝伐单抗治疗的持续性或复发性上皮性卵巢癌或腹膜癌患者的血清CA-125水平的预测价值
4. Probabilistic neural network analysis of quantitative nuclear features in predicting the risk of cancer recurrence at different follow-up times [C] . Petalas P., Spyridonos P., Glotsos D., Image and Signal Processing and Analysis, 2003. ISPA 2003. Proceedings of the 3rd International Symposium on . 2003

机译：定量神经特征的概率神经网络分析可预测不同随访时间的癌症复发风险
5. Dietary and Lifestyle Modifications in the Prevention of Epithelial Ovarian Cancer Recurrence [D] . Torres, Alexandra M. 2017

机译：饮食和生活方式的改变，以预防上皮性卵巢癌复发
6. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172 [O] . Thomas C. Krivak, Chunqiao Tian, G. Scott Rose, -1

机译：与静脉内化疗相比III阶段阶段最佳消泡卵巢癌患者血清CA-125水平的妇科肿瘤群研究：患有GOG患者172患者的分析
7. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial [O] . Leslie M. Randall, Michael W. Sill, Robert A. Burger, 2012

机译：在妇科肿瘤组阶段II试验中对持续或复发上皮卵巢癌患者血清CA-125患者血清CA-125水平的预测值

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

摘要

著录项

相似文献

相关主题

期刊订阅